Finance

Lists
Q2 2027 earnings • released • Revenue beat +1.92%
See results
4543:TYO
Terumo Corp
¥2,461.00
+2.54%
(+61.00) 1D
Nov 16, 3:30:00 PM GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4543...
Open
¥2,430
High
¥2,491
Low
¥2,404
Mkt. cap
3.64T
Avg. vol.
6.54M
Volume
6.75M
Dividend
1.34%
Quarterly dividend
¥8
Ex-dividend date
Sep 29, 2026
P/E ratio
31.96
52-wk high
¥2,689
52-wk low
¥1,900
EPS
¥77
Shares outstanding
370.59M
No. of employees
31K
Open
¥2,430
High
¥2,491
Low
¥2,404
Mkt. cap
3.64T
Avg. vol.
6.54M
Volume
6.75M
Dividend
1.34%
Quarterly dividend
¥8
Ex-dividend date
Sep 29, 2026
P/E ratio
31.96
52-wk high
¥2,689
52-wk low
¥1,900
EPS
¥77
Shares outstanding
370.59M
No. of employees
31K
News stories
From web sources and news partners
Profile
Terumo Corporation was founded in 1921 as Red Line Thermometer Corporation by a group of medical scientists led by Dr. Kitasato Shibasaburō to produce medical thermometers in Japan. The company's first product was "Jintan Taionkei", the first Japanese-made thermometer available for sale, and it has since expanded into a medical devices manufacturer, producing medical disposables, cardiovascular systems and diabetes care products. In 1971, Terumo opened its first overseas office in the United States. Since then, the company has established subsidiaries in Europe, South America, China, India, Philippines, Vietnam, Thailand, Australia and México. The company later expanded its product range to include coronary stents and catheters, and acquired, among others, the cardiovascular specialty companies Vascutek and Microvention in 2002 and 2006 respectively. Wikipedia
About Terumo Corp
CEO-
Employees31.2K
FoundedSep 17, 1921
HeadquartersShibuya, Tokyo, Japan
SectorHealth Care
IndustryMedical device
Last report
Nov 12, 2026
Fiscal period
Q2 2027
- / -
Revenue / Est. (JPY)
312.69B / 306.80B
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
296.63B
300.32B
311.81B
312.69B
Cost of goods sold
143.44B
149.06B
133.27B
146.21B
Cost of revenue
143.44B
149.06B
133.27B
146.21B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
105.26B
107.66B
109.70B
109.58B
Operating expense
109.31B
98.62B
89.06B
114.64B
Total operating expenses
252.74B
247.68B
222.33B
260.85B
Operating income
43.88B
52.64B
89.48B
51.84B
Other non operating income
2.00M
-409.00M
-4.00M
2.00M
EBT including unusual items
45.38B
31.66B
90.32B
-20.80B
EBT excluding unusual items
45.38B
52.86B
90.32B
49.72B
Income tax expense
12.72B
5.30B
19.89B
-4.99B
Effective tax rate
28.04%
16.73%
22.03%
23.98%
Other operating expenses
4.05B
-9.05B
-20.64B
5.06B
Net income
32.65B
26.37B
70.43B
-15.81B
Net profit margin
11.01%
8.78%
22.59%
-5.06%
Earnings per share
-
-
-
-
Interest and investment income
2.21B
-
2.38B
927.00M
Interest expense
-463.00M
-1.32B
-1.48B
-3.05B
Net interest expenses
1.75B
-1.32B
905.00M
-2.12B
Depreciation and amortization charges
-
-
-
-
EBITDA
69.98B
79.07B
116.67B
79.14B
Gain or loss from assets sale
154.00M
188.00M
12.00M
180.00M
Upcoming events
AI content may include mistakes. Learn more
Google apps